QQQ   348.82 (-1.70%)
AAPL   177.82 (-0.78%)
MSFT   323.38 (-3.09%)
META   263.60 (-2.77%)
GOOGL   122.50 (-3.78%)
AMZN   121.23 (-4.25%)
TSLA   224.57 (+1.47%)
NVDA   374.75 (-3.05%)
NIO   7.76 (-1.52%)
BABA   85.29 (-1.63%)
AMD   117.83 (-5.15%)
T   16.09 (+2.68%)
F   13.59 (+5.11%)
MU   67.06 (-0.71%)
CGC   0.72 (-2.69%)
GE   106.08 (+0.59%)
DIS   92.53 (+0.40%)
AMC   4.73 (+1.94%)
PFE   38.89 (+1.36%)
PYPL   64.04 (-1.51%)
NFLX   399.77 (+0.12%)
QQQ   348.82 (-1.70%)
AAPL   177.82 (-0.78%)
MSFT   323.38 (-3.09%)
META   263.60 (-2.77%)
GOOGL   122.50 (-3.78%)
AMZN   121.23 (-4.25%)
TSLA   224.57 (+1.47%)
NVDA   374.75 (-3.05%)
NIO   7.76 (-1.52%)
BABA   85.29 (-1.63%)
AMD   117.83 (-5.15%)
T   16.09 (+2.68%)
F   13.59 (+5.11%)
MU   67.06 (-0.71%)
CGC   0.72 (-2.69%)
GE   106.08 (+0.59%)
DIS   92.53 (+0.40%)
AMC   4.73 (+1.94%)
PFE   38.89 (+1.36%)
PYPL   64.04 (-1.51%)
NFLX   399.77 (+0.12%)
QQQ   348.82 (-1.70%)
AAPL   177.82 (-0.78%)
MSFT   323.38 (-3.09%)
META   263.60 (-2.77%)
GOOGL   122.50 (-3.78%)
AMZN   121.23 (-4.25%)
TSLA   224.57 (+1.47%)
NVDA   374.75 (-3.05%)
NIO   7.76 (-1.52%)
BABA   85.29 (-1.63%)
AMD   117.83 (-5.15%)
T   16.09 (+2.68%)
F   13.59 (+5.11%)
MU   67.06 (-0.71%)
CGC   0.72 (-2.69%)
GE   106.08 (+0.59%)
DIS   92.53 (+0.40%)
AMC   4.73 (+1.94%)
PFE   38.89 (+1.36%)
PYPL   64.04 (-1.51%)
NFLX   399.77 (+0.12%)
QQQ   348.82 (-1.70%)
AAPL   177.82 (-0.78%)
MSFT   323.38 (-3.09%)
META   263.60 (-2.77%)
GOOGL   122.50 (-3.78%)
AMZN   121.23 (-4.25%)
TSLA   224.57 (+1.47%)
NVDA   374.75 (-3.05%)
NIO   7.76 (-1.52%)
BABA   85.29 (-1.63%)
AMD   117.83 (-5.15%)
T   16.09 (+2.68%)
F   13.59 (+5.11%)
MU   67.06 (-0.71%)
CGC   0.72 (-2.69%)
GE   106.08 (+0.59%)
DIS   92.53 (+0.40%)
AMC   4.73 (+1.94%)
PFE   38.89 (+1.36%)
PYPL   64.04 (-1.51%)
NFLX   399.77 (+0.12%)
Most-Upgraded StocksMost-Upgraded
NASDAQ:REGN

Regeneron Pharmaceuticals (REGN) Stock Forecast, Price & News

$738.63
-9.51 (-1.27%)
(As of 06/7/2023 ET)
Compare
Today's Range
$737.82
▼
$746.86
50-Day Range
$725.00
▼
$830.35
52-Week Range
$538.01
▼
$837.55
Volume
468,349 shs
Average Volume
594,826 shs
Market Capitalization
$80.75 billion
P/E Ratio
20.07
Dividend Yield
N/A
Price Target
$854.13
ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability

Regeneron Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.74 Rating Score
Upside/​Downside
15.6% Upside
$854.13 Price Target
Short Interest
Healthy
1.11% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.97
Upright™ Environmental Score
News Sentiment
0.08mentions of Regeneron Pharmaceuticals in the last 14 days
Based on 11 Articles This Week
Insider Trading
Selling Shares
$9.56 M Sold Last Quarter
Proj. Earnings Growth
4.86%
From $34.76 to $36.45 Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.48 out of 5 stars

Medical Sector

133rd out of 982 stocks

Pharmaceutical Preparations Industry

53rd out of 468 stocks

See Top Rated MarketRank™ Stocks Here

REGN stock logo

About Regeneron Pharmaceuticals (NASDAQ:REGN) Stock

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically-humanized mice to produce optimized fully-human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.

Receive REGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Regeneron Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

REGN Stock News Headlines

June 7, 2023 | msn.com
Here's How Much You Would Have Made Owning Regeneron Pharmaceuticals Stock In The Last 10 Years
June 6, 2023 | finance.yahoo.com
26% Of This Regeneron Pharmaceuticals Insider's Holdings Were Sold
June 7, 2023 | Behind the Markets (Ad)
BREAKING: The truth about war with China
Foreign Affairs reports, "China is Now in a Prewar Tempo of Political and Military Preparations." China has one goal: take control of Taiwan, and an invasion could happen any day. I've identified 5 investments I believe are in immediate danger. But you can get out of them now - before it's too late.
June 6, 2023 | finance.yahoo.com
26% Of This Regeneron Pharmaceuticals Insider's Holdings Were Sold \
June 5, 2023 | msn.com
Regeneron Pharmaceuticals Unusual Options Activity For June 05
June 5, 2023 | americanbankingnews.com
Insider Selling: Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) EVP Sells $184,000.00 in Stock
June 4, 2023 | americanbankingnews.com
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Director Sells $73,542.00 in Stock
May 30, 2023 | seekingalpha.com
Regeneron Pharmaceuticals, Inc. (REGN) TD Cowen 4th Annual Oncology Innovation Summit (Transcript)
June 7, 2023 | MarketBeat Internal (Ad)
Get MarketBeat All Access Free for 30 Days
MarketBeat All Access is the premier all-in-one stock research solution that helps you identify the best stocks, monitor your portfolio, and keep track of the market. You get our top stock picks, best-in-class research tools, real-time alerts, proprietary research reports and much more. Try it free for 30 days.
May 27, 2023 | americanbankingnews.com
Brokerages Set Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Target Price at $850.91
May 26, 2023 | finance.yahoo.com
Regeneron (REGN) Posts Upbeat Data From Multiple Myeloma Study
May 26, 2023 | msn.com
Regeneron Reveals Updated Data From Multiple Myeloma Study, Showing Response Rate Of 71%
May 25, 2023 | msn.com
Regeneron Pharmaceuticals Unusual Options Activity For May 25
May 25, 2023 | finance.yahoo.com
Fianlimab (LAG-3 inhibitor) Combined with Libtayo® (cemiplimab) Shows Clinically Meaningful and Durable Tumor Responses Across Key Advanced Melanoma Patient Populations
May 25, 2023 | finance.yahoo.com
Updated Linvoseltamab (BCMAxCD3) Data from Pivotal Trial Demonstrates Early, Deep and Durable Responses in Patients with Heavily Pre-treated Multiple Myeloma
May 25, 2023 | finance.yahoo.com
The Zacks Analyst Blog Highlights AbbVie, Intel, Qualcomm, Regeneron and CME Group
May 25, 2023 | finance.yahoo.com
14 Best Biotech Stocks To Buy According To Hedge Funds
May 22, 2023 | benzinga.com
Here's How Much $100 Invested In Regeneron Pharmaceuticals 20 Years Ago Would Be Worth Today
May 22, 2023 | msn.com
Sanofi-Regeneron Highlight Dupixent Data, Say Drug Benefit Was Swift, Sustained
May 22, 2023 | americanbankingnews.com
Regeneron Pharmaceuticals (NASDAQ:REGN) Now Covered by Analysts at StockNews.com
May 22, 2023 | reuters.com
Sanofi: smoker's lung drug benefit was swift and sustained in trial
May 20, 2023 | finance.yahoo.com
Regeneron Pharmaceuticals' (NASDAQ:REGN) investors will be pleased with their solid 158% return over the last five years
May 19, 2023 | msn.com
Regeneron (REGN) Faces Challenges as Eylea Sales Decline
May 19, 2023 | benzinga.com
High School Scientists and Engineers Win Nearly $9 Million at the Regeneron International Science and Engineering Fair 2023
May 19, 2023 | finance.yahoo.com
High School Scientists and Engineers Win Nearly $9 Million at the Regeneron International Science and Engineering Fair 2023
May 18, 2023 | finance.yahoo.com
Regeneron Applauds Supreme Court’s Unanimous Opinion Striking Down Amgen’s PCSK9 Patent Claims and Supporting Scientific Innovation
May 16, 2023 | seekingalpha.com
Regeneron Pharmaceuticals, Inc. (REGN) 2023 RBC Capital Markets Global Healthcare Conference Transcript
See More Headlines

REGN Price History

REGN Company Calendar

Last Earnings
2/03/2023
Today
6/07/2023
Next Earnings (Estimated)
8/02/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:REGN
CUSIP
75886F10
CIK
872589
Web
www.regeneron.com
Phone
(914) 847-7000
Fax
914-347-2113
Employees
11,851
Year Founded
1988

Price Target and Rating

Average Stock Price Forecast
$854.13
High Stock Price Forecast
$1,050.00
Low Stock Price Forecast
$625.00
Forecasted Upside/Downside
+15.0%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.74
Research Coverage
23 Analysts

Profitability

EPS (Most Recent Fiscal Year)
$36.80
Trailing P/E Ratio
20.19
Forward P/E Ratio
21.38
P/E Growth
2.4
Net Income
$4.34 billion
Net Margins
33.81%
Pretax Margin
37.64%
Return on Equity
20.41%
Return on Assets
15.79%

Debt

Debt-to-Equity Ratio
0.11
Current Ratio
5.45
Quick Ratio
4.67

Sales & Book Value

Annual Sales
$12.17 billion
Price / Sales
6.67
Cash Flow
$44.09 per share
Price / Cash Flow
16.85
Book Value
$207.31 per share
Price / Book
3.58

Miscellaneous

Outstanding Shares
109,330,000
Free Float
99,673,000
Market Cap
$81.23 billion
Optionable
Optionable
Beta
0.23

Social Links


Key Executives

  • Leonard S. SchleiferLeonard S. Schleifer
    Co-President, Chief Executive Officer & Director
  • George Damis YancopoulosGeorge Damis Yancopoulos
    Co-President, Director & Chief Scientific Officer
  • Patrice Gilooly
    Senior VP-Quality Assurance & Operations
  • Robert E. LandryRobert E. Landry
    Chief Financial Officer & Executive VP-Finance
  • Neil StahlNeil Stahl
    Executive VP-Research & Development

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













REGN Stock - Frequently Asked Questions

Should I buy or sell Regeneron Pharmaceuticals stock right now?

23 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Regeneron Pharmaceuticals in the last year. There are currently 1 sell rating, 4 hold ratings and 18 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" REGN shares.
View REGN analyst ratings or view top-rated stocks.

What is Regeneron Pharmaceuticals' stock price forecast for 2023?

23 analysts have issued 12-month price objectives for Regeneron Pharmaceuticals' shares. Their REGN share price forecasts range from $625.00 to $1,050.00. On average, they expect the company's stock price to reach $854.13 in the next year. This suggests a possible upside of 15.0% from the stock's current price.
View analysts price targets for REGN or view top-rated stocks among Wall Street analysts.

How have REGN shares performed in 2023?

Regeneron Pharmaceuticals' stock was trading at $721.49 at the start of the year. Since then, REGN shares have increased by 3.0% and is now trading at $743.00.
View the best growth stocks for 2023 here.

When is Regeneron Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 2nd 2023.
View our REGN earnings forecast.

How were Regeneron Pharmaceuticals' earnings last quarter?

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) released its quarterly earnings results on Friday, February, 3rd. The biopharmaceutical company reported $12.56 EPS for the quarter, beating the consensus estimate of $8.18 by $4.38. The biopharmaceutical company had revenue of $3.41 billion for the quarter, compared to the consensus estimate of $3.11 billion. Regeneron Pharmaceuticals had a trailing twelve-month return on equity of 20.41% and a net margin of 33.81%. The firm's revenue for the quarter was down 31.1% compared to the same quarter last year. During the same quarter last year, the company earned $23.72 earnings per share.
Read the conference call transcript.

What ETFs hold Regeneron Pharmaceuticals' stock?

ETFs with the largest weight of Regeneron Pharmaceuticals (NASDAQ:REGN) stock in their portfolio include Invesco Nasdaq Biotechnology ETF (IBBQ), First Trust US Equity Opportunities ETF (FPX), iShares Biotechnology ETF (IBB), VanEck Biotech ETF (BBH), ProShares Ultra Nasdaq Biotechnology (BIB), Simplify Health Care ETF (PINK), ProShares Nasdaq-100 Dorsey Wright Momentum ETF (QQQA) and Invesco Dynamic Biotechnology & Genome ETF (PBE).

What is Leonard S. Schleifer's approval rating as Regeneron Pharmaceuticals' CEO?

423 employees have rated Regeneron Pharmaceuticals Chief Executive Officer Leonard S. Schleifer on Glassdoor.com. Leonard S. Schleifer has an approval rating of 87% among the company's employees.

What other stocks do shareholders of Regeneron Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Regeneron Pharmaceuticals investors own include NVIDIA (NVDA), Gilead Sciences (GILD), Netflix (NFLX), Tesla (TSLA), Alibaba Group (BABA), Johnson & Johnson (JNJ), Walt Disney (DIS), Micron Technology (MU), Advanced Micro Devices (AMD) and Salesforce (CRM).

What is Regeneron Pharmaceuticals' stock symbol?

Regeneron Pharmaceuticals trades on the NASDAQ under the ticker symbol "REGN."

Who are Regeneron Pharmaceuticals' major shareholders?

Regeneron Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional investors include FMR LLC (8.63%), BlackRock Inc. (8.61%), State Street Corp (4.48%), EP Wealth Advisors LLC (4.16%), Dodge & Cox (2.18%) and Geode Capital Management LLC (2.03%). Insiders that own company stock include Andrew J Murphy, Arthur F Ryan, Arthur F Ryan, Bonnie L Bassler, Bonnie L Bassler, Christine A Poon, Christopher R Fenimore, George L Sing, George Yancopoulos, Huda Y Zoghbi, Joseph J Larosa, Joseph L Goldstein, Joseph L Goldstein, Leonard S Schleifer, Marc Tessier-Lavigne, Marion Mccourt, Michael S Brown, N Anthony Coles, Neil Stahl, P Roy Vagelos, Plew Daniel P Van, Plew Daniel P Van, Robert E Landry and Robert E Landry.
View institutional ownership trends.

How do I buy shares of Regeneron Pharmaceuticals?

Shares of REGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Regeneron Pharmaceuticals' stock price today?

One share of REGN stock can currently be purchased for approximately $743.00.

How much money does Regeneron Pharmaceuticals make?

Regeneron Pharmaceuticals (NASDAQ:REGN) has a market capitalization of $81.23 billion and generates $12.17 billion in revenue each year. The biopharmaceutical company earns $4.34 billion in net income (profit) each year or $36.80 on an earnings per share basis.

How many employees does Regeneron Pharmaceuticals have?

The company employs 11,851 workers across the globe.

Does Regeneron Pharmaceuticals have any subsidiaries?
The following companies are subsidiares of Regeneron Pharmaceuticals: Eastside Campus Holdings LLC, Loop Road Holdings LLC, OSMR Holdings, Old Saw Mill Holdings LLC, Regeneron Assurance Inc., Regeneron Atlantic Holdings, Regeneron Belgium BV, Regeneron Canada Company, Regeneron Capital International B.V., Regeneron Genetics Center LLC, Regeneron GmbH, Regeneron Healthcare Solutions Inc., Regeneron International Holdings LLC, Regeneron International Limited, Regeneron Ireland Designated Activity Company, Regeneron Ireland Holdings Unlimited Company, Regeneron NL B.V., Regeneron Spain S.L.U., Regeneron UK Limited, and Rockwood Road Holdings LLC.
Read More
How can I contact Regeneron Pharmaceuticals?

Regeneron Pharmaceuticals' mailing address is 777 OLD SAW MILL RIVER ROAD, TARRYTOWN NY, 10591. The official website for the company is www.regeneron.com. The biopharmaceutical company can be reached via phone at (914) 847-7000, via email at invest@regeneron.com, or via fax at 914-347-2113.

This page (NASDAQ:REGN) was last updated on 6/7/2023 by MarketBeat.com Staff

My Account -